Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
Molecular and Biological Agricultural Sciences Program, Taiwan International Graduate Program, Academia Sinica and National Chung Hsing University, Taipei 11529, Taiwan.
Biomolecules. 2020 May 9;10(5):738. doi: 10.3390/biom10050738.
Plant type III polyketide synthases produce diverse bioactive molecules with a great medicinal significance to human diseases. Here, we demonstrated versatility of a stilbene synthase (STS) from , which can accept various non-physiological substrates to form unnatural polyketide products. Three enzymes (4-coumarate CoA ligase, malonyl-CoA synthetase and engineered benzoate CoA ligase) along with synthetic chemistry was practiced to synthesize starter and extender substrates for STS. Of these, the crystal structures of benzoate CoA ligase (BadA) from in an form or in complex with a 2-chloro-1,3-thiazole-5-carboxyl-AMP or 2-methylthiazole-5-carboxyl-AMP intermediate were determined at resolutions of 1.57 Å, 1.7 Å, and 2.13 Å, respectively, which reinforces its capacity in production of unusual CoA starters. STS exhibits broad substrate promiscuity effectively affording structurally diverse polyketide products. Seven novel products showed desired cytotoxicity against a panel of cancer cell lines (A549, HCT116, Cal27). With the treatment of two selected compounds, the cancer cells underwent cell apoptosis in a dose-dependent manner. The precursor-directed biosynthesis alongside structure-guided enzyme engineering greatly expands the pharmaceutical repertoire of lead compounds with promising/enhanced biological activities.
植物型 III 聚酮合酶产生具有重要医学意义的多种生物活性分子,可用于治疗人类疾病。在这里,我们展示了来自 的芪合酶(STS)的多功能性,它可以接受各种非生理底物,形成非天然的聚酮产物。我们使用三种酶(4-香豆酸辅酶 A 连接酶、丙二酰辅酶 A 合成酶和工程苯甲酸辅酶 A 连接酶)以及合成化学方法来合成 STS 的起始和延伸底物。其中,来自 的苯甲酸辅酶 A 连接酶(BadA)的晶体结构以 形式或以与 2-氯-1,3-噻唑-5-羧酸-AMP 或 2-甲基噻唑-5-羧酸-AMP 中间产物的复合物形式在 1.57 Å、1.7 Å 和 2.13 Å 的分辨率下分别被确定,这增强了其生产不寻常 CoA 起始物的能力。STS 表现出广泛的底物混杂性,有效地提供了结构多样的聚酮产物。七种新型产物对一系列癌细胞系(A549、HCT116、Cal27)表现出所需的细胞毒性。用两种选定的化合物处理后,癌细胞以剂量依赖性方式发生细胞凋亡。前体定向生物合成以及结构导向的酶工程极大地扩展了具有潜在/增强生物活性的先导化合物的药物库。